Parkinson’s disease

Nov 04, 2026

The human brain is guarded by one of biology's most selective security systems, and it turns away nearly every large-molecule drug that tries to get in. Cracking the blood-brain barrier (BBB) has become one of the most competitive races in modern biotech, with the first approved transferrin-receptor "shuttle" biolo...

Oct 23, 2026

Summary Vascular dementia is the second most common form of dementia after Alzheimer’s disease; however, no drug has been specifically approved for its treatment.  In 2025, the total number of diagnosed prevalent cases of vascular dementia across the seven major markets was estimated at 3 million, with ...

Oct 09, 2026

Summary On September 28, 2026, the FDA approved AbbVie’s JUVMO (tavapadon) as the first selective dopamine D1/D5 receptor agonist for adults with Parkinson’s disease, introducing a new dopaminergic approach after decades dominated by levodopa and D2/D3 agonists. The approval was supported by findings from the T...

Sep 29, 2026

Roche Reports Positive Interim Data Showing Sefaxersen Significantly Reduces Proteinuria in IgA Nephropathy Roche announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The trial achieved it...

Jul 29, 2026

For most of medical history, the brain has been the one organ we could describe but barely touch. Today, that's changing fast. A new wave of devices, implants, and algorithms is learning to listen to the brain's electrical language, and, increasingly, to talk back to it. This convergence of neuroscience, engineerin...

Nov 06, 2025

Parkinson’s disease is a progressive neurodegenerative disorder that primarily affects movement, causing tremors, stiffness, and balance problems. The condition develops when nerve cells in the brain that produce dopamine, a chemical that helps control muscle movements, become damaged or die. As one of the most com...

Nov 04, 2025

Intensity Therapeutics Publishes Compelling Clinical Data for INT230-6 in Advanced Cancers Intensity Therapeutics, Inc. (Nasdaq: INTS) announced the publication of its Phase 1/2 clinical results for INT230-6. The comprehensive study evaluated the intratumoral therapy's safety, efficacy, and mechanism of action a...

Oct 28, 2025

Wireless brain sensors are emerging as a transformative technology in neuroscience and healthcare, offering a new level of precision, comfort, and real-time monitoring for patients with neurological conditions. Unlike traditional wired sensors that limit mobility and can cause discomfort, wireless brain sensors use...

Aug 22, 2025

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a constellation of symptoms impacting both the autonomic nervous system and motor function. According to the National Organization for Rare Disorders (NORD), MSA affects between 15,000 and 50,000 individuals in the United Sta...

May 27, 2025

Parkinson’s disease is a complex and progressive neurodegenerative disorder that affects millions worldwide, with its prevalence expected to rise due to aging populations and environmental factors. Characterized by a gradual decline in motor and non-motor functions, the disease significantly impacts the quality of ...